Shire (SHPG) Reaches New 1-Year Low at $130.38

Shire PLC (NASDAQ:SHPG)’s share price reached a new 52-week low on Wednesday . The company traded as low as $130.38 and last traded at $130.42, with a volume of 866529 shares. The stock had previously closed at $133.97.

SHPG has been the subject of a number of analyst reports. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research cut Shire from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. FBR & Co initiated coverage on Shire in a report on Thursday, October 19th. They issued a “buy” rating and a $201.00 price target for the company. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a report on Thursday, November 16th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a research report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $212.50.

The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The stock has a market capitalization of $39,231.38, a PE ratio of 23.64, a PEG ratio of 0.70 and a beta of 1.41.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.86 by ($0.49). Shire had a net margin of 10.95% and a return on equity of 14.41%. analysts predict that Shire PLC will post 15 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Commerzbank Aktiengesellschaft FI boosted its position in shares of Shire by 22.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 375 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Shire by 6.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $1,073,000 after buying an additional 381 shares during the period. Pitcairn Co. boosted its position in shares of Shire by 26.5% in the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 401 shares during the period. Thompson Investment Management Inc. boosted its position in shares of Shire by 5.2% in the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 468 shares during the period. Finally, Verition Fund Management LLC boosted its position in shares of Shire by 18.9% in the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 472 shares during the period. 20.31% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Shire (SHPG) Reaches New 1-Year Low at $130.38” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2018/02/09/shire-shpg-reaches-new-1-year-low-at-130-38.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply